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A neuro-inflammatory response is evident in Alzheimer’s disease (AD), yet the precise mechanisms by which
neuro-inflammation influences the progression of Alzheimer’s disease (AD) remain poorly understood. Type-1
interferons (IFNs) are master regulators of innate immunity and have been implicated in multiple CNS disorders,
however their role in AD progression has not yet been fully investigated. Hence, we generated APPSWE/PS1ΔE9 mice
lacking the type-1 IFN alpha receptor-1 (IFNAR1, APPSWE/PS1ΔE9 x IFNAR1
−/−) aged to 9 months to investigate the
role of type-1 IFN signaling in a well-validated model of AD. APPSWE/PS1ΔE9 x IFNAR1
−/− mice displayed a modest
reduction in Aβ monomer levels, despite maintenance of plaque deposition. This finding correlated with partial
rescue of spatial learning and memory impairments in the Morris water maze in comparison to APPSWE/PS1ΔE9
mice. Q-PCR identified a reduced type-1 IFN response and modulated pro-inflammatory cytokine secretion in
APPSWE/PS1ΔE9 x IFNAR1
−/− mice compared to APPSWE/PS1ΔE9 mice. Interestingly, immunohistochemistry displayed
enhanced astrocyte reactivity but attenuated microgliosis surrounding amyloid plaque deposits in APPSWE/PS1ΔE9 x
IFNAR1−/− mice in comparison to APPSWE/PS1ΔE9 mice. These APPSWE/PS1ΔE9 x IFNAR1
−/− microglial populations
demonstrated an anti-inflammatory phenotype that was confirmed in vitro by soluble Aβ1-42 treatment of IFNAR1−/−
primary glial cultures. Our findings suggest that modulating neuro-inflammatory responses by suppressing type-1 IFN
signaling may provide therapeutic benefit in AD.
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Pathologically, Alzheimer’s disease (AD) is characterized
by the extracellular accumulation of Aβ plaques [60]
and presence of neurofibrillary tangles containing
hyper-phosphorylated tau [22]. Yet targeting these
proteinopathies has yet proven clinically efficacious
[47]. Neuro-inflammation, involving pro-inflammatory
cytokine secretion and reactive gliosis, is evident in
AD [34, 37, 38, 48, 54] and epidemiological evidence
suggests that this innate immune process is a key
contributor to disease pathogenesis [6, 59, 67]. However* Correspondence: juliett@unimelb.edu.au; pcrack@unimelb.edu.au
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neuro-inflammation in AD remains unclear.
Oligomeric and fibrillar Aβ are detected by pattern
recognition receptors of the innate immune system and
trigger inflammasome activation [57, 58]. Many studies
have utilized the APPSWE/PS1ΔE9 mouse model of AD as
a tool to investigate in vivo inflammasome activation in
response to Aβ production. These mice displays elevated
production of Aβ1-42, leading to progressive plaque de-
position and cognitive decline beginning at 6–9 months
of age [30, 31]. Removal of the NLRP3 inflammasome,
critical for caspase-1-mediated production of IL-1β, in
APPSWE/PS1ΔE9 mice confers reductions in Aβ load,
enhances LTP and rescues cognitive impairments [26]. A
supportive study addressing the NLRP1 inflammasome
also demonstrated that a reduced IL-1β response to
amyloid is beneficial in APPSWE/PS1ΔE9 mice andle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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antibodies blocking IL-12/IL-23 signaling attenuate amyloid
burden and cognitive defects in APPSWE/PS1ΔE9 mice [66].
Findings from these studies suggest that microglial
phenotype and function play an important role in the
exacerbation and progression of AD. Upon stimulus
with pro-inflammatory cytokines, microglia can polarize
towards a pro-inflammatory phenotype that is deleteri-
ous to neurogenesis and synaptic plasticity. Microglial
populations can also adopt an alternate anti-
inflammatory phenotype that results from exposure to
anti-inflammatory cytokines and promotes resolution of
inflammation considered to be neuro-protective [45, 55].
These aforementioned studies demonstrate that targeting
pro-inflammatory cytokine networks can attenuate neuro-
inflammation, promote Aβ clearance and confer cognitive
benefit in mouse models of AD by promoting anti-
inflammatory activity of microglia. However, Adenoviral
delivery of anti-inflammatory cytokines IL-4 or IL-10
results in deleterious effects, impeding Aβ clearance and
worsening cognitive decline [10, 11]. In contrast complete
removal of IL-10 promotes innate immunity and mitigates
AD-like pathology in APPSWE/PS1ΔE9 mice [23]. Clearly a
greater understanding of pro- and anti-inflammatory cyto-
kine signaling is required to explain how modulating
innate neuro-inflammation impacts progression of AD.
The pleiotropic type-1 IFNs regulate the aforemen-
tioned pro-inflammatory cytokine systems and are mas-
ter regulators of the innate immune response [19, 33].
By signalling through the type-1 interferon receptor
alpha-1 (IFNAR1) and activating the Janus associated
kinase/Signal transducer and activator of transcription
(JAK/Stat) pathway, type-1 IFNs can induce pro-
inflammatory gene transcription generating hallmark
cytokines (IL-1β, IL-6 and TNFα) that regulate immune
cell recruitment and inflammatory progression. Whilst
their contribution to peripheral immunity is well docu-
mented, type-1 IFNs are produced and trigger inflamma-
tory cascades in CNS residing neurons and microglia
[14, 52]. Elevated type-1 IFN levels have been linked to
exacerbation numerous neuro-pathologies including
Aicardi-Goutieres syndrome [17, 18] and systemic lupus
erythromatosus [8]. It is now considered that a balance
of interferon signalling is required for healthy brain
physiology and dysregulation of this cytokine system can
result in brain ‘interferonopathies’ [20]. Significantly, an
exacerbated type-1 IFN response contributes to many
deleterious effects associated with the aging process [3].
In addition, a type-1 IFN signature in both human AD
patients and APPSWE/PS1ΔE9 mice is evident and re-
moval IFNAR1 confers protection against soluble Aβ1-
42-induced toxicity in primary cultured neurons [64].
We hypothesize that removal of type-1 IFN signaling
attenuates neuro-inflammation and delays phenotypicprogression in APPSWE/PS1ΔE9 mice. To test this, we
generated APPSWE/PS1ΔE9 x IFNAR1
−/− mice and used
primary mixed astrocyte and microglial cultures and pri-
mary neuronal cultures to investigate the role of type-1
IFN signaling in AD. We find that APPSWE/PS1ΔE9 x
IFNAR1−/− mice display modest reductions in mono-
meric Aβ load, without altering plaque deposition, and
improved spatial cognitive performance. These mice
exhibit a predominantly anti-inflammatory glial phenotype
when compared to APPSWE/PS1ΔE9 mice alone. We con-
firm this anti-inflammatory glial phenotype in vitro in re-
sponse to Aβ1-42 and demonstrate this polarization state
protects primary neuronal cultures. Importantly, this
study demonstrates that removal of type-1 IFN signaling
modulates neuro-inflammation and retards phenotypic
progression in the APPSWE/PS1ΔE9 mouse model of AD.
Materials and Methods
Animals
APPSWE/PS1ΔE9 transgenic mice [30] on a C57BL/6
background were sourced from JAX. (B6.Cg-Tg(APPs-
we,PSEN1dE9)85Dbo/Mmjax, JAX ID: 005864, https://
www.jax.org/strain/005864). IFNAR1−/− mice on a
C57Bl/6 background were initially generated by [28].
APPSWE/PS1ΔE9 transgenic mice lacking IFNAR1 were
generated by interbreeding. APPSWE/PS1ΔE9 and
IFNAR1−/− mice to produce F1 progeny. APPSWE/PS1ΔE9
x IFNAR1
+/− mice from F1 progeny were then interbred
to yield APPSWE/PS1ΔE9 x IFNAR1
−/− mice (F2 progeny).
In all animal experiments, mice were used at 9 months
of age with aged-matched littermate non-transgenic
wildtype and IFNAR1−/− control mice. All mice were
determined as specific pathogen-free, housed in sterile
micro-isolator cages and fed ad-libitum on standard
chow with open access to water. All animal procedures
were performed in accordance with the University of
Melbourne animal care committee’s regulations.
Animal genotyping
All animals used in this study were analysed for correct
genotypes before use. This genotyping was either per-
formed manually (Additional file 1: Figure S1), as
described below, or in partnership with Transnetyx™
(Cordova, TN, USA).
Tails from mice were obtained pre-weaning and gen-
omic DNA was extracted. Tissue was digested using
Proteinase K (9.3 mg/ml, New England Biolabs) in Tris
buffer (containing 1 % w/v SDS). Upon removal of pro-
tein with Potassium acetate (1.5 M) and precipitation
using propan-2-ol, the extracted DNA was washed in
70 % Ethanol and reconstituted in Tris-EDTA (TE)
buffer. PCR was then conducted using the GoTaq®
DNA polymerase system (M3005, Promega) under the
following conditions:
Step # Temperature (°C) Time (seconds) Comments
1 94 180




6 4 ∞ Holding temperature
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Et-Br-labelled (40 μg/ml) gel and electrophoresis was
performed to separate bands. A pre-stained BenchTop
100 bp DNA ladder (G8291, Promega) was used to de-
termine sample band sizes upon gel imaging using the
ChemiDoc™ MP image system (Biorad). Specific oligo-
nucleotide primers used for amplification of APPSWE,
PS1ΔE9, IFNAR1 and internal control DNA sequences
are detailed below:Primer name Direction
(5’→ 3’)





























Reverse GTA GGT GGA AAT TCT









Reverse TGG TGC TTA TAC ACT




Forward GAG GCA GCG CGG CTA
TCG TG
0.5 μMIn vivo study structure
The number of mice used in this study were as follows:
Wildtype: 15; IFNAR1−/−: 18; APPSWE/PS1ΔE9; APPSWE/
PS1ΔE9 x IFNAR1
−/−: 9. Both male and female mice were
used in the study in 50:50 proportion. No significant sex
difference was detected in behavior and/or biochemical
readouts and thus sexes were pooled. All mice were sub-
jected to Morris water testing then 9 mice from each geno-
type were randomly selected for biochemical processing.
Half hemispheres were taken for immunohistochemistry,whilst the other half was snap frozen and ground on liquid
nitrogen in order to isolate both protein and RNA from the
same mice.
Mixed cortical and hippocampal glial isolation
Mixed cortical and hippocampal neurons were isolated
from embryonic P0-1 embryos as previously described
[35]. Briefly, cortices were isolated and meninges surgi-
cally removed. The cleaned cortical tissue was then
digested in hanks buffered sulphate solution (HBSS,
14025–092, Gibco) using trypsin/DNAse (1 mg/ml,
T9201, D5025, Sigma) until a single cell suspension was
achieved. Cells were then plated at a density of 1 brain/
10 ml in culture medium (DMEM, 31985–062, Gibco,
20 % FBS, 0.5 % penicillin-streptomycin) in T75cm2
flasks. Media was then replaced every two days until the
glial cultures formed a comprehensive monolayer. Cells
were seeded at 5 x 105 cells/ml for experimental use
between 14 and 28 days in vitro.
Mixed cortical and hippocampal neuron isolation
Mixed cortical and hippocampal neurons were isolated
as described previously [63]. Briefly, cortices were iso-
lated from embryonic day 14–16 pups and meninges
were removed. Cleaned cortices were then digested in
Krebs solution containing trypsin (250 μg/ml) and
DNAse (33 μg/ml) and mechanically agitated to ensure a
single cell suspension. Cells were then plated into pre-
coated Poly-L-lysine (0.5 mg/ml, P6282, sigma) plastic
ware at a density of 1 x 106 cells/ml in neurobasal media
(17504–044, Gibco) containing B-27 growth factor sup-
plement (17504–044, Gibco), L-glutamine (500 μM,
G7513, Sigma) and 2 % FBS. The following day, FBS was
removed from the media and cultures were supple-
mented with fresh culture media every two days until
experimental use. Neuronal purity was assessed at >90 %
using NeuN (neuronal nuclei) immunohistochemistry
(data not shown) and all cultures were used day 9–10
in vitro.
Cardiac perfusion of mice and isolation of brain tissue
Mice were deeply anaesthetized using intra-peritoneal
injection of combinatorial ketamine (90 mg/kg) and
xylazine (4.5 mg/kg, K113, Sigma). Mice were cardiac
perfused with ice-cold heparinized PBS (1U/ml, H3393,
Sigma). Brains were then excised and separated for use
in immunohistochemistry or for RNA/protein biochem-
ical analysis. Isolation of the cortex for RNA/protein bio-
chemistry was performed using a modified dissection
technique [24]. Hemispheres were placed on an ice cold
glass dissection plate and orientated in a sagittal plane.
The cerebellum was removed, and the striatum, thalamus,
midbrain and brain stem remnants were identified. These
structures were then removed using sterilized blunt
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wall of the cortex. The hippocampus was then peeled
away from the cortex, and cortical tissue was snap frozen
in liquid nitrogen and stored at −80 °C until required.
Immunohistochemistry
For immunohistochemical analysis, hemispheres were
post-fixed in 4 % w/v paraformaldehyde in PBS for 72 h
(4 °C) before being transferred into 30 % w/v sucrose in
PBS for 48 h (4 °C) and embedded in Optimal Cutting
Temperature (OCT, 4583, Sakura) medium for subse-
quent cryosectioning. Sagittal sections (30 μm) were
then cut throughout the hippocampal region using a
cryostat (Reichert-Jung) and mounted onto electrostatic
Menzel-Gläser Superfrost® plus glass microscopy slides
(J1800AMNZ, Thermo-Scientific). Tissue was then
permeabilized in PBS-T (0.05 % v/v Tween-20, 5 min,
room temperature) and blocked in CAS-Block™ (1 h,
room temperature, 008120, Invitrogen). After rinsing
with PBS, tissue was then incubated overnight with pri-
mary antibody diluted in 10 % v/v CAS-Block™ in PBS
(4 °C, humidified chamber). After washing in PBS, slides
were then incubated with fluorescent secondary anti-
bodies diluted in 10 % v/v CAS-Block™ in PBS (2 h,
room temperature). Post-PBS rinse coverslips were
mounted in Vectashield® DAPI-containing mounting
media (H-1200, Vector laboratories). Images were then
obtained using a Zeiss Axio Observer.Z1 (Carl Zeiss im-
aging) inverted fluorescence microscope. Details of anti-
bodies used for immunohistochemistry are provided below:Antibody Supplier Source Dilution
GFAP Dako (Z0334) Rabbit pAb 1:1000
IBA-1 Wako (019–19741) Rabbit pAb 1:300
WO-2 (Wun et al., 2008 [68]) Mouse mAb
IgG1
1:500









Goat pAb 1:1000To quantify plaque number and burden, WO-2
immunofluorescent labelled sections were converted to
8-Bit images and an image fluorescence threshold was
set using Image J quantification software (NIH). Plaque
staining was then analysed by particle quantification giv-
ing plaque number. The WO-2 positive pixel coverage
value was then expressed relative to total cortical area to
calculate cortical plaque burden. For IBA-1 and GFAP
immunofluorescence quantification, integrated densities
were calculated from entire cortical regions using ImageJ quantification software (National Institutes of Health,
NIH). These values were then normalized to staining
background and expressed as relative fluorescence inten-
sity as described previously [32]. All quantified data is
from average values generated from ≥3 sections/mouse
(each 270 μm apart or every 6th section).
Amyloid beta preparation and cell culture treatment
Amyloid peptide stocks were prepared according to
methods described previously [2]. Aβ1-42 stocks (A-42-
T-1, GenecBio) were initially monomerized in 1, 1, 1, 3,
3, 3-Hexafluoro-2-propanol (0.5 mg/ml, HFIP, 52512,
Fluka), lyophilized and stored at −80 °C until required.
The peptide was then dissolved in ice cold 5 mM NaOH
in Dulbecco’s PBS by rigorous vortexing and protein
concentration was determined by absorbance spectro-
photometry at 214 nm. Peptide concentrations were
calculated using Eq. 1.
Aβ42½  ¼ Abs214x DF=εð Þ ð1Þ
Where Abs214 = Absorbance value of sample at 214 nm,
DF = Sample dilution factor, ε =molar extinction coeffi-
cient of Aβ42 (75,887 L/mol/cm).
Primary cultured glial cells were treated with 10 μM
Aβ1-42 or NaOH vehicle for up to 96 h in serum-
reduced glial treatment medium (DMEM with 2 % FBS
and 0.5 % penicillin-streptomycin). The final concentra-
tion of NaOH across all treatment groups was <5nM
and remained non-toxic.
Protein extraction
Following treatment, primary glial cell cultures were
washed in ice cold PBS and collected via cell scraping.
Cell pellets were briefly sonicated in Tris lysis buffer
(50 mM Tris, 150 mM NaCl, 1 % v/v Triton x-100
(T8787, Sigma), 1 % w/v SDS, PhosphoSTOP® phosphat-
ase and cOmplete® protease inhibitors (04906837001,
11697498001, Roche), pH 7.4). Brain tissue was homoge-
nized in Tris lysis buffer (≤100 mg/ml concentration,
without 1%w/v SDS). Upon rotation for 90 min at 4 °C,
homogenates were centrifuged (12,000xg, 4 °C, 5 min)
before supernatants were removed and stored at −80 °C
until required. Protein concentrations were determined
as per the method of Bradford ([5], 500–0006, Bio-Rad).
SDS-PAGE gel electrophoresis and Western blotting
Fifty micrograms of protein was denatured in reducing
buffer (20 mM Tris, 20%v/v glycerol, 4%w/v SDS, 10 %
β-mecaptoethanol (M6250, Sigma), and bromophenol
blue). Samples were loaded onto 10 % SDS-PAGE gels
(60 mM Tris, 0.1 % w/v SDS, 0.1 % w/v APS, 0.01 % v/v
TEMED, 10 % Acrylamide/Bis (161–0156, Bio-Rad)) or
4-20 % Mini-PROTEAN® TGX Stain-Free™ gels (456–
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120 V in Novex® Tris-Glycine SDS running buffer
(LC2675-5, Invitrogen). Proteins were then transferred
to polyvinylidene fluoride (PVDF) membranes by semi-
dry transfer (60 mA/gel, 1.25 h) or using the TransBlot®
Turbo™ transfer system (2.5MA, 7 min, 170–4155, Bio-
Rad) as per manufacturer’s instructions. Membranes
were blocked in 5%w/v skim milk powder in Tris buff-
ered saline-Tween 20 (0.05 % v/v Tween-20, TBS-T) for
1 h before overnight incubation with primary antibodies
at 4 °C (dilutions in 2 % w/v skim milk powder in TBS-T).
Membranes were then washed in TBS-T before being in-
cubated with horseradish peroxidase (HRP)-conjugated
secondary antibodies (dilutions in 2 % w/v skim milk pow-
der in TBS-T) for 90 min at room temperature. HRP sig-
nals were detected using an enhanced chemiluminescence
(ECL™) prime Western blotting detection kit (RPN2232,
Amersham) and visualized using the ChemiDoc™ MP
system (Bio-Rad). For densitometry analysis, all raw pixel
intensities of HRP signals from Western blots were calcu-
lated using Image J quantification software (NIH). Details
of antibodies used for Western blotting are provided
below:Antibody Supplier Source WB
dilution
p-Stat-3 (Y705) Cell Signaling (9145) Rabbit mAb
IgG1
1:1000
Stat-3 Cell Signaling (9132) Rabbit pAb 1:1000





Cell Signaling (3033) Rabbit mAb
IgG1
1:1000






G α-rabbit/HRP Dako (P0448) Goat pAb-HRP 1:1000
G α-mouse/HRP Dako (P0447) Goat pAb-HRP 1:1000
Step # Temperature (°C) Time (minutes) Comments
1 50 2 -
2 94.5 10 -
3 97 0.5 X40 repeats
4 59.7 1Aβ1:40 sandwich Enzyme-linked immunosorbent assay
(ELISA)
For quantification of soluble and insoluble Aβ levels, tis-
sues were homogenized in PBS (containing Triton x-100,
1 % v/v, PBS-T) containing PhosphoSTOP® phosphatase
and cOmplete® protease inhibitors (04906837001,
11697498001, Roche), pH 7.4) via sonication. After centri-
fugation (100,000xg, 60 min, 4 °C) the supernatant was
collected to detect PBS-T-soluble Aβ1:40 levels. The
remaining tissue pellets were further homogenized in
70 % v/v formic acid in PBS, centrifuged (100,000xg,
60 min, 4 °C) and the resulting supernatant wasneutralized with 1 M Tris base (20x volume) and collected
to detect PBS-T-insoluble Aβ1:40 levels by sandwich
ELISA.
Assays were run in 96-well plate format with all stan-
dards and samples run in duplicate reactions. ELISA
plates were coated in WO-2 capture antibody (diluted in
0.05 M carbonate-bicarbonate, pH 9.6) overnight and
blocked in 1 % BSA (diluted in TBS-T) prior to sample
incubation (100 μg protein/well, 4 °C, overnight incuba-
tion with shaking). Plates were then washed in TBS-T
and incubated with an anti-Aβ1:40 casein-1E8 biotinyl-
ated monoclonal sandwich detection antibody. After
washing in TBS-T plates were incubated with high sensi-
tivity Streptavidin-HRP and signals were developed using
TMB substrate and detection at 450 nm. Sample ab-
sorbance were normalized to the Aβ1:40 standard
curve and concentrations are expressed relative to
sample total protein concentrations as determined by
Bradford assay.RNA isolation and cDNA synthesis
RNA was extracted from cell pellets or brain tissue by
methods previously described [12] using TRIzol® reagent
(15596018, Life-Technologies). Contaminating genomic
DNA was then removed prior to reverse transcription
using the TURBO DNA-free™ kit (AM1907, Ambion) ac-
cording to manufacturer’s guidelines. Yield quantities
and purity of the RNA product was then assessed using
the nanodrop 1000 spectrophotometer (Thermo Scientific).
One microgram of RNA was then reverse transcribed to
produce cDNA using a high capacity cDNA reverse
transcription kit (4368814, Applied Biosciences) as
per manufacturer’s instructions and cDNA was then
diluted 1:3 in diethylpyrocarbonate (DEPC)-treated
dH2O for use in QPCR.Quantitative PCR
All QPCR was performed in standard 384-well plates
(4309849, Applied Biosystems) using the 7900ht fast
real-time PCR system (Applied Biosystems) and reac-
tions for a given sample were performed in triplicate.
All Taqman gene expression assays were purchased
commercially (431182, Applied Biosystems) and reac-
tions were performed under the following thermal
conditions:
Gene Direction (5’→ 3’) Sequence (5’→ 3’)
GAPDH Forward ATCTTCTTGTGCAGTGCCAGC
Reverse ACTCCACGACATACTCAGCACC
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primers were synthesized commercially (Geneworks)
and reactions were performed under the following thermal
conditions:Step # Temperature (°C) Time (minutes) Comments
1 95 20 -
2 95 0.5 X40 repeats
3 60 1.5
4 95 15 -
5 60 15 -



















Reverse CACGGCACCTCCTAAATTGTFold change readouts presented throughout the study
were calculated using the ΔΔct calculation method [36].
For each experiment a fluorescence detection threshold
was automatically set at 1.0 RFU and the cycle number
at which each reaction reached this threshold was calcu-
lated (cycle threshold (Ct)). Triplicate Ct value for genes
of interest were then normalized back to the Ct values
of the GAPDH housekeeping gene to account for differ-
ences in original cDNA concentration between samples
(ΔCt). The calculated ΔCt of treatment or genotype
groups were then normalized back to the ΔCt of
appropriate genotype-specific control samples. In
addition, ΔΔCt values were converted to fold change
data using Eq. 2.
Fold change ¼ 2 −ΔΔctð Þ ð2Þ










TREM2 Mouse Mm04209422_m1MTS cell viability assay
Cell viability was measured by the ability to metabolize
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS, CellTiter 96®
AQueous non-radioactive cell proliferation assay, G5421,
Promega) in the presence of the electron coupler phena-
zine methosulfate (PMS) to a media soluble formazan
product, as described previously [9]. Combined MTS
(400 μg/ml) and PMS (44 μg/ml) solution was incubated
on primary cultured neurons for 4 h (37 °C). Culture
medium absorbance at 492 nm was then determined using
a Multiskan Ascent spectrophotometer (Thermo Scien-
tific). All sample absorbance readings were then blank
normalized using a negative control reaction containing
only culture medium and the MTS/PMS reagent. Absorb-
ance readings of all treatment groups were then normal-
ized back to genotype-specific vehicle controls and
expressed as a percentage of vehicle control cell viability.
Experiments were performed in technical triplicate and
staurosporine (1 μM, S6942, Sigma) was used to induce
cellular apoptosis in primary neuronal cultures for positive
control means.
Morris water maze
Morris water maze (MWM) testing was conducted in a
black circular pool 1.6 m in diameter and 0.8 m deep. A
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to the enclosure 25 cm from the pool wall. The pool was
then filled with water at 21–23 °C until the white plat-
form was submerged 1 cm below the surface. Non-toxic,
water soluble white ceiling paint (Taubmans) was then
used to opacify the water. The room was brightly illumi-
nated using wall-mounted halogen lamps. Several dis-
tinct and distal extra-maze cues were placed around the
pool as points of reference. These cues remained in
place throughout the duration of testing and the plat-
form was only removed to conduct the probe trial.
Mice were subjected to a 4 trial/day protocol for 7 days
with 60 s maximum trial duration. Mice were removed
from their test cage and placed into the water maze, at a
randomized cardinal point, facing towards the pool wall.
The 60 s trial commenced after the mouse had entered
the MWM for 2 s. If the test mouse found, mounted
and stayed on the hidden platform for 2 s the trial was
deemed complete and latency to reach the platform was
calculated. The mouse remained on the hidden platform
for 20 s before being removed from the water maze and
placed back in their testing cage. If the mouse failed to
find or remain on the platform for at least two seconds
before the 60 s time allowance, the researcher entered
the testing area and guided the mouse to the hidden
platform. Once an individual mouse completed the trial
and was towel dried, the next mouse within the testing
group was immediately placed into the MWM for test-
ing. Each mouse underwent 4 trials per day, according
to the aforementioned trial parameters and had an
inter-trial resting time of 10 min. All MWM testing
was recorded to DVD and automatically tracked using
Ethovision® XT (Noldus). For all individual trials, latency
to platform, success rate, path length and swim speed was
calculated. A 60 s value for latency was awarded for all tri-
als where the test mouse failed to find the platform within
the allocated time.
To assess spatial reference memory, a probe trial was
conducted on day 7 of MWM acquisition. Mice were
placed into the maze at the north cardinal point and
allowed to explore for the standard 60 s trial length with
the escape platform removed. The maze was virtually di-
vided up into quadrants and time spent in the quadrant
which previously held the platform was calculated. All
primary readouts reported from MWM testing conducted
in this study are well-established in the AD field [7].
Statistical analysis
GraphPad Prism software (version 6.0, http://
www.graphpad.com/scientific-software/prism/) was used
for all t-tests, ANOVAs and post-hoc statistical evalu-
ation. Where comparisons of multiple groups was re-
quired a one or two-way analysis of variance (ANOVA)
was performed, with mouse genotype as the fixedvariable. A Bonferroni post-hoc or Tukey’s HSD multiple
comparisons test was then performed. Otherwise an
unpaired two-tailed Student’s t-test was used. For all
statistical tests a two-tailed α value of 0.05 was utilized.
Box plots were used to display data in which the midline
represents the median value and the upper and lower
margins equate to the 25 % and 75 % quartiles. The
whiskers display data within the 1.5xinterquartile range
and values beyond this were determined as outliers (rep-
resented as circles). All other numerical data is pre-
sented as mean ± SEM. Power values for each test where
calculated post-hoc using G*Power (version 3.1, http://
gpower.hhu.de/), based upon the effect size, group num-
ber and sample size. Exact p-values were calculated for
all Student’s t-tests and multiplicity adjusted p-values
were determined for all Bonferroni’s and Tukey’s post-
hoc tests. A p-value <0.05 was considered statistically
significant. All use of statistics is detailed in Additional
file 2: Table S1.
Results
Removal of IFNAR1 in APPSWE/PS1ΔE9 mice confers
modest reductions in cortical Aβ monomer load but
plaque burden remains unaltered
To investigate the effect of removing type-1 IFN signal-
ing in AD we generated APPSWE/PS1ΔE9 x IFNAR1
−/−.
APPSWE/PS1ΔE9 mice aged 9 months display an en-
hanced type-1 IFN and pro-inflammatory cytokine re-
sponse [64]. Hence, we focused on characterizing
phenotypic alterations in APPSWE/PS1ΔE9 x IFNAR1
−/−
mice at this age. With variable hippocampal Aβ plaque
deposition at this age in both APPSWE/PS1ΔE9 and
APPSWE/PS1ΔE9 x IFNAR1
−/− mice (data not shown),
the current study focused on cortical regions only, not
hippocampus. To assess potential alterations in Aβ
plaque burden, immunohistochemistry was performed
on APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/−
mouse brain sagittal sections, stained with anti-Aβ mAb
WO-2 (n = 9 per genotype, Fig. 1a, b). Both APPSWE/
PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mice display
extensive plaque deposition within cortical regions but
no difference was detected between genotypes when Aβ
plaques were counted (n = 9 per genotype, Fig. 1c) or
when cortical plaque burden percentage was quantified
(n = 9 per genotype, Fig. 1d). To validate these immuno-
histochemical findings we prepared PBS-T-soluble and
PBS-T-insoluble fractions from cortical tissue to quantify
Aβ levels by ELISA. We did not observe any differences
in PBS-T-soluble or PBS-T-insoluble Aβ1:40 levels mea-
sured from cortical tissue lysates of APPSWE/PS1ΔE9 and
APPSWE/PS1ΔE9 x IFNAR1
−/− mice (n = 4–6 per geno-
type, Fig. 1e, d). These findings suggest that removal of
type-1 IFN signaling in APPSWE/PS1ΔE9 mice does not
influence amyloid plaque deposition at 9 months of age.
Fig. 1 (See legend on next page.)
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Fig. 1 Removal of IFNAR1 in APPSWE/PS1ΔE9 mice confers modest reductions in Aβ monomer levels but not plaque burden. Representative
cortical sections from 9 month old a APPSWE/PS1ΔE9 and b APPSWE/PS1ΔE9 x IFNAR1
−/− mice stained with anti-Aβ mAb WO-2 using fluorescence
immunohistochemistry (scale bar = 200 μm). c Aβ plaques were counted from entire cortical regions of APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x
IFNAR1−/− mice (3 sections per mouse, •represents outlier value). d Cortical plaque burden was calculated by quantifying Aβ plaque immunofluorescence
relative to total cortical area from these same cortical slices of APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mice. e PBS-T-soluble and f PBS-T-insoluble
Aβ1:40 levels in APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1−/− mouse cortical lysates were quantified by ELISA. g Representative immunoblot of
Tris–HCl soluble cortical protein lysates isolated from 9 month old wildtype, IFNAR1−/−, APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mice using the
anti-Aβ mAb WO-2. Multiple amyloid species can be detected including endogenous APP-CTF (muAPP-CTF), transgenic APP-CTF (TgAPP-CTF), Aβ
trimers (3-mer) and Aβ monomers. A long exposure (LE) was used to enhance detection of Aβ monomer levels. Densitometry of h
Transgenic APP-CTF, i endogenous murine APP-CTF, j Aβ monomer and k 3-mer levels in APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1−/− mice is shown.
All densitometry is expressed as a ratio of Aβmonomer:β-actin or Aβ trimer:β-actin raw pixel intensities. Immuno-detection of β-actin was used to ascertain
loading quantities. Data is presented as box plots described in the statistical analysis section in Materials and Methods (immunohistochemistry: n= 9 per
genotype; ELISA and Western blotting: n= 6 (APPSWE/PS1ΔE9), n= 4 (APPSWE/PS1ΔE9 x IFNAR1
−/−); *p < 0.05, ****p < 0.0001). See Additional file 2: Table S1
for further analysis
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APPSWE/PS1ΔE9 IFNAR1
−/− mouse, the oligomerization
state of soluble Aβ species may be altered. This can influ-
ence peptide toxicity and potentially impact cognitive phe-
notypes [1, 15, 44]. To investigate the oligomerization state
of various Aβ species, we analyzed Tris–HCl soluble cor-
tical fractionations from wildtype, IFNAR1−/−, APPSWE/
PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mice by western
blotting, probed with anti-Aβ mAb WO-2 (n = 4–6 per
genotype, Fig. 1g). Analysis of Aβ oligomers in wildtype
and IFNAR1−/− mice displayed constitutive Aβ production
but not overexpression that is characteristic of the
APPSWE/PS1ΔE9 transgene. Densitometry identified a trend,
albeit not statistically significant, to decreased transgenic
human APP-CTF expression (n = 4–6 per genotype, p =
0.0618, Fig. 1h) and significant reductions in endogenous
murine APP-CTF levels (n = 4–6 per genotype, p < 0.0001,
Fig. 1i) in APPSWE/PS1ΔE9 x IFNAR1
−/− mice compared to
APPSWE/PS1ΔE9 mice. Densitometry confirmed a signifi-
cant 4.3 ± 0.2-fold decrease of cortical Aβ monomer levels
in APPSWE/PS1ΔE9 x IFNAR1
−/− mice compared to
APPSWE/PS1ΔE9 mice (n = 4–6 per genotype, p = 0.0122,
Fig. 1j). Although not statistically significant, Aβ trimer (3-
mer) levels also trended to a decrease in APPSWE/PS1ΔE9 x
IFNAR1−/− mice compared to APPSWE/PS1ΔE9 mice (n =
4–6 per genotype, p = 0.0569, Fig. 1k). Collectively, this
data highlights that removal of IFNAR1 in APPSWE/PS1ΔE9
mice does not influence Aβ plaque deposition, but may in-
fluence oligomerization through modest, but significant,
reductions in Aβ monomer levels.
Spatial learning and memory defects in APPSWE/PS1ΔE9
mice are improved upon removal of IFNAR1
To assess if removal of type-1 IFN signaling can alleviate
the cognitive deficits observed in APPSWE/PS1ΔE9 we an-
alyzed spatial learning and memory performance of wild-
type, IFNAR1−/−, APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x
IFNAR1−/− mice using the Morris water maze. Com-
pared to wildtype, APPSWE/PS1ΔE9 mice required moretime to find the escape platform, whilst APPSWE/PS1ΔE9
x IFNAR1−/− mice were initially impaired but recovered
to wildtype levels as pheno-copied by IFNAR1−/− mice
(n = 9–18 per genotype, 0.05 < p < 0.001, Fig. 2a). Com-
pared to wildtype, an initial decline in trial success rate
was seen for all genotypes but this was only maintained
by the APPSWE/PS1ΔE9 mice over the course of acquisi-
tion (n = 9–18 per genotype, 0.05 < p < 0.0001, Fig. 2b).
Compared to wildtype, all genotypes initially selected
longer escape paths but only APPSWE/PS1ΔE9 mice
maintained this abnormality throughout testing (n = 9–
18 per genotype, p < 0.01, Fig. 2c). Representative tracks
(Day 7 acquisition) of APPSWE/PS1ΔE9 mice display a
lack of cue-directed swimming to find the platform, par-
tially rectified in the APPSWE/PS1ΔE9 IFNAR1
−/− coun-
terparts. Wildtype and IFNAR1−/− behaved similarly
(Fig. 2d, Additional file 2: Table S1 for detailed analysis).
After the 7 day acquisition period, the escape platform
was removed from the maze and persistence of the
mouse to escape was measured. Although not statisti-
cally significant, APPSWE/PS1ΔE9 x IFNAR1
−/− mice
spent more time exploring the escape quadrant than
APPSWE/PS1ΔE9 mice (APPSWE/PS1ΔE9: 27.3 ± 3.8 % vs.
APPSWE/PS1ΔE9 x IFNAR1
−/−: 39.0 ± 7.7 %, n = 9–18 per
genotype, p = 0.5111, Fig. 2e). Interestingly, IFNAR1−/−
mice spent a significantly greater amount of time in the
escape quadrant than APPSWE/PS1ΔE9 mice (IFNAR1
−/−:
45.6 ± 0.5 % vs. APPSWE/PS1ΔE9: 27.3 ± 3.8 %, n = 9–18
per genotype, p = 0.0488, Fig. 2e). As swimming ability
can represent a potential confounding factor in the Mor-
ris water maze, average swim speed was measured.
APPSWE/PS1Δ9 mice swim at a significantly lower vel-
ocity than their wildtype counterparts (Wildtype: 18.5 ±
0.5 cm/s vs. APPSWE/PS1Δ9: 15.9 ± 0.4 cm/s, n = 9–18
per genotype, p = 0.0025, Fig. 2f ); however this difference
at a physiological level is minor and observed swimming
technique remained consistent amongst genotypes.
Collectively, this data implicates that removal of type-1
IFN signaling in APPSWE/PS1ΔE9 mice rescues spatial
Fig. 2 APPSWE/PS1ΔE9 x IFNAR1
−/− mice are spared from cognitive impairment. Wildtype, IFNAR1−/−, APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/−
littermate controls 9 months of age were subjected to Morris water maze testing to assess spatial learning and memory. All mice were tested using a
7-day hidden platform acquisition (4trials/day) with probe trial protocol as described in Materials and Methods. Primary water maze readouts of a
average trial latency, b trial success rate and c trial path length (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, WT vs. APPSWE/PS1ΔE9; θp < 0.05, θθp
< 0.01, θθθp < 0.001, θθθθp < 0.0001, WT vs. APPSWE/PS1ΔE9 x IFNAR1−/−; +p < 0.05, ++p < 0.01, +++p < 0.001 WT vs. IFNAR1−/−). d Representative
automated tracks from day 7 testing is shown for all genotypes. e After day 7 acquisition the escape platform is removed from the maze and mice are
introduced into the maze for a final trial. Quantification of the time spent in the platform containing quadrant for all genotypes is shown. The dashed
line (y = 25 %) represents the percentage of time spent in the escape quadrant that would be solely due to random chance as opposed to preference
(p < 0.05). f Calculation of average swim velocity across all 7 days of testing is shown for all genotypes (**p < 0.01). Data is displayed as mean ± SEM or
box plots described in the statistical analysis section in Materials and Methods (n = 14 (APPSWE/PS1ΔE9), n = 9 (APPSWE/PS1ΔE9 x IFNAR1
−/−), n = 18
(IFNAR1−/−), n = 15 (wildtype)). See Additional file 2: Table S1 for further analysis
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water maze.
The type-1 IFN and pro-inflammatory cytokine response
is attenuated in APPSWE/PS1ΔE9 x IFNAR1
−/− mice
Previously it has been demonstrated that removal of
IFNAR1 attenuates the type-1 IFN response to solubleAβ1-42 in primary cultured neurons and confers neuro-
protection [64]. To investigate alterations in the type-1
IFN response in APPSWE/PS1ΔE9 x IFNAR1
−/− mice, Q-
PCR was performed on cortical tissue. Levels of IFNα
expression were significantly elevated in APPSWE/PS1ΔE9
mice compared to wildtype mice with this elevation atten-
uated in APPSWE/PS1ΔE9 x IFNAR1
−/− mice (Wildtype:
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0.0009; APPSWE/PS1ΔE9: 3.4 ± 0.8-fold vs. APPSWE/PS1ΔE9
x IFNAR1−/−: 1.3 ± 0.1-fold, p = 0.0063, n = 9 per genotype,
Fig. 3a). This data confirms that aged APPSWE/PS1ΔE9 dis-
play enhanced type-1 IFNα expression that is IFNAR1-
dependent. We also analyzed IFNβ transcript levels in
both wildtype and APPSWE/PS1ΔE9 cortical tissue but were
unable to detect a difference between genotypes (n = 7 per
genotype, Additional file 3: Figure S2).
As IRF7 and IRF3 are critical mediators of IFNα [27]
and IFNβ [56] production respectively, mRNA levels
were also analyzed to assess the capacity for type-1 IFNFig. 3 The type-1 IFN and pro-inflammatory cytokine response is attenuate
tissue isolated from 9 month old wildtype, IFNAR1−/−, APPSWE/PS1ΔE9 and A
and IRF8 transcript levels. b Representative immunoblot of Tris–HCl soluble
APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mice using anti-p-Stat-3. c
PS1ΔE9 x IFNAR1
−/− mice is shown. d Q-PCR of cortical tissue isolated from
IFNAR1−/− littermate controls analyzing IL-1β, IL-6 and TNFα transcript level
housekeeping gene GAPDH (ΔCt). The mRNA of the variant genotype grou
mate controls (fold change, ΔΔCt). For densitometry, total Stat-3 levels wer
calculated relative to this value (p-Stat-3/(Stat-3/β-actin). Intensity values of
expressed as fold change relative to wildtype littermate control levels (repr
ascertain loading quantities. Data are displayed as box plots box plots
Methods (Q-PCR: n = 9 per genotype; Western blotting: n = 4 per genot
****p < 0.0001). See Additional file 2: Table S1 for further analysisproduction in these mice. Levels of IRF7 expression were
significantly elevated in APPSWE/PS1ΔE9 mice compared
to wildtype mice, implying elevated capacity for IFNα
production in these mice (Wildtype: 1.1 ± 0.08-fold vs.
APPSWE/PS1ΔE9: 2.2 ± 0.3-fold, p < 0.0001, n = 9 per
genotype, Fig. 3a). This elevation in IRF7 was attenuated
in APPSWE/PS1ΔE9 x IFNAR1
−/− mice (APPSWE/PS1ΔE9:
2.2 ± 0.3-fold vs. APPSWE/PS1ΔE9 x IFNAR1
−/−: 0.3 ±
0.03-fold, p < 0.0001, n = 9 per genotype, Fig. 3a). Inter-
estingly, IFNAR1−/− mice exhibit basal reductions in
IRF7 expression levels compared to wildtype mice
(Wildtype: 1.1 ± 0.08-fold vs. IFNAR1−/−: 0.2 ± 0.02-fold,d upon removal of IFNAR1 in APPSWE/PS1ΔE9 mice. a Q-PCR of cortical
PPSWE/PS1ΔE9 x IFNAR1
−/− littermate controls analyzing IFNα, IRF7, IRF3
cortical protein lysates isolated from 9 month old wildtype, IFNAR1−/−,
Densitometry of cortical p-Stat-3 levels in APPSWE/PS1ΔE9 and APPSWE/
9 month old wildtype, IFNAR1−/−, APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x
s. For Q-PCR, all samples were normalized back to the Ct value of the
ps were then expressed relative to their gene-specific wildtype litter-
e normalized to the β-actin loading control and p-Stat-3 intensity was
the APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mouse groups are
esented by the dashed line). Immunodetection of β-actin was used to
described in the statistical analysis section in Materials and
ype; •represents outlier value; *p < 0.05, **p < 0.01, ***p < 0.001,
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of IRF3 were significantly elevated in APPSWE/PS1ΔE9
mice compared to wildtype mice (Wildtype: 1.1 ± 0.06-
fold vs. APPSWE/PS1ΔE9: 1.5 ± 0.1-fold, p = 0.0004, n = 9
per genotype, Fig. 3a). However no alteration was de-
tected when IRF3 levels in APPSWE/PS1ΔE9 mice were
compared to APPSWE/PS1ΔE9 x IFNAR1
−/−, implying
that signaling through IFNAR1 does not regulate IRF3
expression in these mice (APPSWE/PS1ΔE9: 1.5 ± 0.1-fold
vs. APPSWE/PS1ΔE9 x IFNAR1
−/−: 1.4 ± 0.09-fold, p =
0.4369, n = 9 per genotype, Fig. 3a). We also analyzed
transcript levels of IRF8, a type-1 IFN-regulated medi-
ator important in microglial activation and phenotype
[40]. Levels of IRF8 expression were significantly ele-
vated in APPSWE/PS1ΔE9 mice compared to wildtype
mice (Wildtype: 1.1 ± 0.07-fold vs. APPSWE/PS1ΔE9: 1.7
± 0.2-fold, p = 0.0009, n = 9 per genotype, Fig. 3a) and
this elevation was maintained in APPSWE/PS1ΔE9 x
IFNAR1−/− mice (APPSWE/PS1ΔE9: 1.7 ± 0.2-fold vs.
APPSWE/PS1ΔE9 x IFNAR1
−/−: 1.9 ± 0.1-fold, p = 0.3845,
n = 9 per genotype, Fig. 3a).
Considering type-1 IFNs signal via the JAK-Stat cas-
cade and induce pro-inflammatory cytokine transcrip-
tion, phosphorylation of Stat-3 was analyzed as a
reporter of net type-1 IFN signaling in the APPSWE/
PS1ΔE9 x IFNAR1
−/− mice. Western blotting confirmed
elevated phosphorylation of Stat-3 in APPSWE/PS1ΔE9
mice compared to both wildtype and IFNAR1−/− mice
(n = 4 per genotype, Fig. 3b). Densitometry of these blots
identified a trend for decreased Stat-3 activation in
APPSWE/PS1ΔE9 x IFNAR1
−/− mice compared to
APPSWE/PS1ΔE9 mice (APPSWE/PS1ΔE9: 2.4 ± 0.8-fold vs.
APPSWE/PS1ΔE9 x IFNAR1
−/−: 1.1 ± 0.4-fold, p = 0.1955,
n = 4 per genotype Fig. 3c). Collectively, these data highlight
that removal of IFNAR1 attenuates the type-1 IFN response
in aged APPSWE/PS1ΔE9 mice, correlating with cognitive
benefits and modest reductions in Aβ monomer load.
Type-1 IFNs are master regulators of the innate im-
mune response, regulating pro-inflammatory cytokine
production [33]. To investigate if the removal of type-1
IFN signaling alters pro-inflammatory cytokine secretion
in APPSWE/PS1ΔE9 mice, Q-PCR analyzing cortical tissue
was performed. IL-1β mRNA transcript levels were up-
regulated in the APPSWE/PS1ΔE9 mice compared wild-
type mice (Wildtype: 1.1 ± 0.09-fold vs. APPSWE/PS1ΔE9:
3.1 ± 0.4-fold, p < 0.0001, n = 9 per genotype, Fig. 3d).
Interestingly, APPSWE/PS1ΔE9 x IFNAR1
−/− mice dis-
played elevated IL-1β mRNA levels compared to
APPSWE/PS1ΔE9 mice alone (APPSWE/PS1ΔE9: 3.1 ± 0.4-
fold vs. APPSWE/PS1ΔE9 x IFNAR1
−/−: 4.5 ± 0.5-fold, p =
0.0071, n = 9 per genotype, Fig. 3d). Whilst IL-6 expres-
sion levels were significantly elevated in APPSWE/PS1ΔE9
mice when compared to wildtype mice, this response
was not significantly altered in APPSWE/PS1ΔE9 xIFNAR1−/− mice (Wildtype: 1.1 ± 0.1-fold vs. APPSWE/
PS1ΔE9: 2.0 ± 0.2-fold, p = 0.0005, n = 9 per genotype,
Fig. 3d). TNFα mRNA transcript levels were upregulated
in the APPSWE/PS1ΔE9 mice compared wildtype mice
(Wildtype: 1.0 ± 0.09-fold vs. APPSWE/PS1ΔE9: 2.2 ± 0.2-
fold, p < 0.0001, n = 9 per genotype, Fig. 3d) Significantly,
TNFα expression was reduced in the APPSWE/PS1ΔE9
IFNAR1−/− mice compared to APPSWE/PS1ΔE9 counter-
parts (APPSWE/PS1ΔE9: 2.2 ± 0.2-fold vs. APPSWE/PS1ΔE9
x IFNAR1−/−: 1.4 ± 0.1-fold, p = 0.0037, n = 9 per genotype,
Fig. 3d). These data suggest that type-1 IFN signaling
through IFNAR1 is an important regulator of pro-
inflammatory cytokine expression in APPSWE/PS1ΔE9 mice.
APPSWE/PS1ΔE9 x IFNAR1
−/− mice exhibit enhanced
astrocyte reactivity but attenuated microgliosis
surrounding amyloid deposition
Both microgliosis and astrocyte reactivity are important
hallmarks of the neuro-inflammation evident in AD and
are primary sources of pro-inflammatory cytokine pro-
duction [25]. To establish if removal of type-1 IFN sig-
naling alters astrocyte reactivity in APPSWE/PS1ΔE9 mice,
immunohistochemistry was performed. Representative
images and fluorescence quantification of sagittaly sec-
tioned cortex revealed a significant 2.2 ± 0.3-fold increase
in GFAP reactivity in APPSWE/PS1ΔE9 x IFNAR1
−/− mice
compared to APPSWE/PS1ΔE9 counterparts (p = 0.0006,
n = 9 per genotype, Fig. 4a, b). High power magnifica-
tion images demonstrate this elevated astrocyte re-
activity surrounds Aβ plaques, generating a localized
inflammatory environment (Fig. 4c). Collectively, this
data highlights that removal of IFNAR1 triggers increased
astrocyte reactivity in cortical areas of Aβ accumulation in
APPSWE/PS1ΔE9 mice. However, further investigation is re-
quired to conclude if this is a compensatory or direct effect
of removing type-1 IFN signaling in APPSWE/PS1ΔE9 mice.
To assess if ablation of type-1 IFN signaling affects
microgliosis in APPSWE/PS1ΔE9 mice further immuno-
histochemistry was performed. Representative images
and fluorescence quantification of sagittaly sectioned
cortex revealed a significant 1.5 ± 0.09-fold decrease in
IBA-1 reactivity in APPSWE/PS1ΔE9 x IFNAR1
−/− mice
compared to APPSWE/PS1ΔE9 counterparts (p = 0.0032,
n = 9 per genotype, Fig. 4d, e). High power magnification
images demonstrate a hypertrophic and reactive micro-
glial phenotype surrounding Aβ plaques in the APPSWE/
PS1ΔE9 mice. IBA-1 positive cells detected in APPSWE/
PS1ΔE9 x IFNAR1
−/− display decreased staining intensity
and remain embedded within plaque deposition, adopt-
ing a different morphology than cells in APPSWE/PS1ΔE9
mice (Fig. 4f ). These findings suggest that ablation of
type-1 IFN signaling in APPSWE/PS1ΔE9 mice attenuates
cortical microgliosis and alters cellular morphology
within the amyloid plaque microenvironment.
Fig. 4 (See legend on next page.)
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Fig. 4 Astrocyte reactivity is elevated but microgliosis is dampened in APPSWE/PS1ΔE9 x IFNAR1
−/− mice. a Representative cortical sections from
9 month old APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mice stained with anti-GFAP using fluorescence immunohistochemistry. b Integrated
density values of positive GFAP immunofluorescence were calculated from entire cortical regions of APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mice (3 sections per mouse). c High power magnification images of APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mouse cortical sections
triple-labelled with DAPI, anti-GFAP and anti-WO-2. d Representative cortical sections from 9 month old APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x
IFNAR1−/− mice stained with anti-IBA-1 using fluorescence immunohistochemistry. e Integrated density values of positive IBA-1 immunofluorescence
were calculated from entire cortical regions of APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mice (3 sections per mouse). f High power magnification
images of APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mouse cortical sections triple-labelled with DAPI, anti-IBA-1 and anti-WO-2. b Scale bars: low
power = 200 μm; high power = 30 μm. All data is displayed as box plots described in the statistical analysis section in Materials and Methods (n = 9 per
genotype; •represents outlier value; **p < 0.01, ***p < 0.001). See Additional file 2: Table S1 for further analysis
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anti-inflammatory glial phenotypic markers in APPSWE/
PS1ΔE9 mice
It has been suggested that pro-inflammatory microglial
phenotypes enhance are largely deleterious in AD
whereas anti-inflammatory microglial activity can pro-
mote beneficial inflammatory resolution [53]. We have
shown that altered gliosis, decreased type-1 IFN re-
sponses and altered pro-inflammatory cytokine secretion
is evident in APPSWE/PS1ΔE9 x IFNAR1
−/− mice, thus we
were interested in assessing expression of glial inflam-
matory phenotypic markers. Cortical tissue from wild-
type, IFNAR1−/−, APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x
IFNAR1−/− mice were analyzed by Q-PCR for pro- and
anti-inflammatory glial phenotype markers.
Elevation of iNOS pro-inflammatory marker expres-
sion was confirmed in APPSWE/PS1ΔE9 mice compared
to wildtype mice (Wildtype: 1.1 ± 0.1-fold vs. APPSWE/
PS1ΔE9: 2.6 ± 0.4-fold, p < 0.0001, n = 9 per genotype,
Fig. 5a). Significantly, iNOS expression was decreased in
APPSWE/PS1ΔE9 x IFNAR1
−/− mice compared to
APPSWE/PS1ΔE9 mice alone (APPSWE/PS1ΔE9: 2.6 ± 0.4-
fold vs. APPSWE/PS1ΔE9 x IFNAR1
−/−: 1.4 ± 0.1-fold, p =
0.0053, n = 9 per genotype, Fig. 5a). Transcript levels of
the pro-inflammatory marker CD11b were elevated in
APPSWE/PS1ΔE9 mice compared to wildtype mice
(Wildtype: 1.0 ± 0.07-fold vs. APPSWE/PS1ΔE9: 2.4 ± 0.4-
fold, p = 0.0014, n = 9 per genotype, Fig. 5a). Similar to
the iNOS expression, CD11b transcript levels were de-
creased in APPSWE/PS1ΔE9 x IFNAR1
−/− mice com-
pared to APPSWE/PS1ΔE9 mice alone (APPSWE/PS1ΔE9:
2.4 ± 0.4-fold vs. APPSWE/PS1ΔE9 x IFNAR1
−/−: 1.4 ±
0.1-fold, p = 0.0371, n = 9 per genotype, Fig. 5a). Expres-
sion of the CD32 pro-inflammatory marker was ele-
vated in APPSWE/PS1ΔE9 mice compared to wildtype,
however this elevation was not suppressed in APPSWE/
PS1ΔE9 x IFNAR1
−/− mice (Wildtype: 1.1 ± 0.1-fold vs.
APPSWE/PS1ΔE9: 3.7 ± 0.6-fold, p < 0.0001, n = 9 per
genotype, Fig. 5a). Indeed, CD32 levels in APPSWE/
PS1ΔE9 x IFNAR1
−/− mice were elevated compared to
wildtype mice albeit not to the same levels as APPSWE/
PS1ΔE9 mice (Wildtype: 1.1 ± 0.1-fold vs. APPSWE/
PS1ΔE9 x IFNAR1
−/−: 2.5 ± 0.3-fold, p = 0.0366, n = 9 pergenotype, Fig. 5a). Expression of the CD33 pro-
inflammatory marker was elevated in APPSWE/PS1ΔE9
mice compared to wildtype, but this elevation was not
suppressed in APPSWE/PS1ΔE9 x IFNAR1
−/− mice
(Wildtype: 1.0 ± 0.05-fold vs. APPSWE/PS1ΔE9: 1.9 ± 0.3-
fold, p = 0.0015, n = 9 per genotype, Fig. 5a).
Analysis of the anti-inflammatory marker TGFβ re-
vealed elevated expression levels in APPSWE/PS1ΔE9 x
IFNAR1−/− mice compared to wildtype mice (Wildtype:
1.0 ± 0.06-fold vs. APPSWE/PS1ΔE9 x IFNAR1
−/−: 1.6 ±
0.2-fold, p = 0.0189, n = 9 per genotype, Fig. 5b). This
elevation was not present in the APPSWE/PS1ΔE9 cohort.
Transcript levels of the YM1 anti-inflammatory marker
were also elevated in APPSWE/PS1ΔE9 x IFNAR1
−/− mice
when compared to both wildtype and APPSWE/PS1ΔE9
mice (Wildtype: 1.2 ± 0.2-fold vs. APPSWE/PS1ΔE9 x
IFNAR1−/−: 2.5 ± 0.5-fold, p = 0.0061; APPSWE/PS1ΔE9:
1.4 ± 0.2-fold vs. APPSWE/PS1ΔE9 x IFNAR1
−/−: 2.5 ± 0.5-
fold, p = 0.0490, n = 9 per genotype, Fig. 5b). ARG1 anti-
inflammatory marker expression levels were elevated in
APPSWE/PS1ΔE9 x IFNAR1
−/− mice when compared to
both wildtype and APPSWE/PS1ΔE9 cohorts (Wildtype:
1.2 ± 0.1-fold vs. APPSWE/PS1ΔE9 x IFNAR1
−/−: 3.0 ± 0.5-
fold, p = 0.0002; APPSWE/PS1ΔE9: 1.7 ± 0.2-fold vs.
APPSWE/PS1ΔE9 x IFNAR1
−/−: 3.0 ± 0.5-fold, p = 0.0141,
n = 9 per genotype, Fig. 5b). Expression levels of both
CD206 and CCL22 M2 markers remained constant
amongst all genotypes (n = 9 per genotype, Fig. 5b).
Transcript levels of the TREM2 anti-inflammatory
marker were elevated in APPSWE/PS1ΔE9 x IFNAR1
−/−
mice when compared to both wildtype and APPSWE/
PS1ΔE9 mice (Wildtype: 1.0 ± 0.07-fold vs. APPSWE/
PS1ΔE9 x IFNAR1
−/−: 2.5 ± 0.2-fold, p < 0.0001; APPSWE/
PS1ΔE9: 2.0 ± 0.1-fold vs. APPSWE/PS1ΔE9 x IFNAR1
−/−:
2.5 ± 0.2-fold, p = 0.0056, n = 9 per genotype, Fig. 5b). Of
interest is the finding that elevations in TREM2 expres-
sion were not unique to the APPSWE/PS1ΔE9 x IFNAR1
−/− genotype but also observed in APPSWE/PS1ΔE9 mice
when compared to wildtype counterparts (Wildtype: 1.0
± 0.07-fold vs. APPSWE/PS1ΔE9: 2.0 ± 0.1-fold, p < 0.0001,
n = 9 per genotype, Fig. 5b). Western blot analysis of the
anti-inflammatory marker SOCS-3, a negative regulator
of type-1 IFN signaling and cytokine production [61,
Fig. 5 Removal of IFNAR1 in APPSWE/PS1ΔE9 mice shifts the microglial phenotype to an anti-inflammatory state. a Q-PCR of cortical tissue isolated
from 9 month old wildtype, IFNAR1−/−, APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− littermate controls analyzing iNOS, CD11b, CD32 and CD33
pro-inflammatory glial marker expression levels. b Q-PCR of cortical tissue isolated from 9 month old wildtype, IFNAR1−/−, APPSWE/PS1ΔE9 and
APPSWE/PS1ΔE9 x IFNAR1
−/− littermate controls analyzing TGFβ, YM1, ARG1, CD206, CCL22 and TREM2 anti-inflammatory glial marker expression
levels. c Immunoblot of Tris–HCl soluble cortical protein lysates isolated from 9 month old wildtype, IFNAR1−/−, APPSWE/PS1ΔE9 and APPSWE/PS1ΔE9
x IFNAR1−/− mice using anti-SOCS-3. Comparative summaries of d Pro-inflammatory and e anti-inflammatory glial marker expression in APPSWE/
PS1ΔE9 and APPSWE/PS1ΔE9 x IFNAR1
−/− mice are displayed. For Q-PCR, all samples were normalized back to the Ct value of the housekeeping
gene GAPDH (ΔCt). The mRNA of the variant genotype groups were then expressed relative to their gene-specific wildtype littermate controls.
For western blotting, immunodetection of β-actin was used to ascertain loading quantities. Data are displayed as mean alone or as box plots described
in the statistical analysis section in Materials and Methods (n = 9 per genotype; •represents outlier value; *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001). See Additional file 2: Table S1 for further analysis
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IFNAR1−/− mice compared to APPSWE/PS1ΔE9 counter-
parts. This up-regulation was also confirmed in IFNAR1
−/− mice alone when compared to wildtype mice
(Fig. 5c).
From the summarized data depicting pro-
inflammatory (Fig. 5d) and anti-inflammatory glial
phenotypic marker expression (Fig. 5e), these findings
implicate that removal of type-1 IFN signaling shifts the
glial phenotype from a pro-inflammatory phenotype
towards an anti-inflammatory and presumably neuro-
protective phenotype in APPSWE/PS1ΔE9 mice.Removal of IFNAR1 attenuates the type-1 IFN and
pro-inflammatory cytokine response in response to
Aβ1-42 in primary glial cultures
Astrocytes and microglia are key contributors to the in-
flammatory phenotype in AD and are also sources of
type-1 IFN production within the CNS [51]. To investigate
the role of astroglial and microglial type-1 IFN production
in response to Aβ1-42, the predominant Aβ species over-
produced in APPSWE/PS1ΔE9 mice [30, 31], we adopted an
in vitro approach using primary cultured mixed glial cul-
tures. Wildtype and IFNAR1−/− glia were treated with
10 μM Aβ1-42 for 24–96 h and Q-PCR was used to assess
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IFNAR1−/− glia displayed reduced IFNα (72 h: Wildtype:
12.7 ± 1.8-fold vs. IFNAR1−/−: 1.4 ± 0.1-fold, p < 0.0001;
96 h: Wildtype: 9.1 ± 4.4-fold vs. IFNAR1−/−: 1.3 ± 0.2-fold,Fig. 6 The type-1 IFN and pro-inflammatory cytokine response to Aβ1-42 i
of primary wildtype and IFNAR1−/− glial cultures treated with 10 μM Aβ1-4
levels. b Representative immunoblot of primary wildtype and IFNAR1−/− gl
(p65). c Densitometry of p-NFkB (p65) levels in primary wildtype and IFNAR
all samples were normalized back to the Ct value of the housekeeping gen
expressed relative to their gene-specific vehicle controls (fold change, ΔΔCt). F
to β-actin levels. All intensity values of Aβ1-42 treated groups are expressed a
of which is represented by the dashed line). Immunodetection of β-actin was
(Q-PCR: n = 4 (wildtype), n = 5 (IFNAR1−/−); Western blotting: n = 3 per genoty
Table S1 for further analysisp = 0.0007, n = 4–5 per genotype, Fig. 6a) and IFNβ ex-
pression (72 h: Wildtype: 6.4 ± 1.3-fold vs. IFNAR1−/−:
0.7 ± 0.2-fold, p = 0.0006; 96 h: Wildtype: 6.3 ± 2.1-fold
vs. IFNAR1−/−: 0.9 ± 0.3-fold, p = 0.0012, n = 4–5 pers attenuated upon removal of IFNAR1 in primary cultured glia. a Q-PCR
2 for 24–96 h analyzing IFNα, IFNβ, IL-1β, IL-6 and TNFα transcript
ial cultures treated with 10 μM Aβ1-42 for 24–72 h using anti-p-NFkB
1−/− glial cultures treated with 10 μM Aβ1-42 for 24–72 h. For Q-PCR
e GAPDH (ΔCt). The mRNA of the Aβ1-42 treatment groups was then
or densitometry raw intensities of p-NFkB (p65) bands were normalized
s fold change relative to the genotype-specific vehicle control (average
used to ascertain loading quantities. Data are displayed as mean ± SEM
pe; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). See Additional file 2:
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contrast to our in vivo data, Western blotting and sub-
sequent densitometry revealed that Aβ1-42 treatment did
not induce a p-Stat-3 response in either wildtype or
IFNAR1−/− glial cultures, displaying a comparable expres-
sion level (Additional file 4: Figure S3). Overall these find-
ings identify a glial-derived type-1 IFN response to Aβ1-42.
Furthermore this type-1 IFN response is attenuated upon
removal of IFNAR1, in line with the notion that IFNAR1 is
critical in autocrine up-regulation of type-1 IFNs in re-
sponse to inflammatory stimuli [13, 29].
To investigate if ablation of type-1 IFN signaling de-
creases the pro-inflammatory cytokine burden in Aβ1-42-
treated glial cultures, further Q-PCR analysis was con-
ducted. At 24 and 48 h post-treatment, the IL-1β response
to Aβ1-42 was decreased in IFNAR1−/− cultures compared
to wildtype glia (24 h: Wildtype: 10.9 ± 4.4-fold vs. IFNAR1
−/−: 0.8 ± 0.4-fold, p = 0.0105; 48 h: Wildtype: 10.8 ± 3.8-fold
vs. IFNAR1−/−: 0.4 ± 0.1-fold, p = 0.0074, n = 4–5 per geno-
type, Fig. 6a). Wildtype glia generated an elevated IL-6 re-
sponse upon Aβ1-42 insult that was attenuated in IFNAR1
−/− cultures at 96 h (Wildtype: 2.7 ± 0.9-fold vs. IFNAR1−/−:
0.3 ± 0.04-fold, p = 0.0259, n = 4–5 per genotype, Fig. 6a).
Expression of TNFα after 24 and 96 h of Aβ1-42 treatment
was also reduced in IFNAR1−/− glia compared to wildtype
counterparts (24 h: Wildtype: 7.2 ± 2.6-fold vs. IFNAR1−/−:
0.6 ± 0.05-fold, p = 0.0003; 96 h: Wildtype: 4.8 ± 0.4-fold vs.
IFNAR1−/−: 0.2 ± 0.09-fold, p = 0.0034, n = 4–5 per geno-
type, Fig. 6a). These data suggest that type-1 IFN signaling
regulates further pro-inflammatory cytokine production in
glial cells exposed to Aβ1-42.
Type-1 IFNs can regulate the activity of NFkB, which
is required for robust immune responses [50, 65]. To ascer-
tain if attenuation of the type-1 IFN and pro-inflammatory
cytokine response to Aβ1-42 observed in IFNAR1−/− glial
cultures resulted in reduced NFkB (p65) activation, further
western blotting was performed (n = 3 per genotype,
Fig. 6b). Densitometry quantification identified phosphor-
ylation of NFkB (p65) was decreased in Aβ1-42-treated
IFNAR1−/− glia across the entire treatment course when
compared to wildtype cultures (24 h: Wildtype: 2.2 ± 0.2-
fold vs. IFNAR1−/−: 0.9 ± 0.08-fold, p = 0.0001; 48 h: Wild-
type: 2.1 ± 0.1-fold vs. IFNAR1−/−: 1.2 ± 0.08-fold, p =
0.0007; 72 h: Wildtype: 1.8 ± 0.2-fold vs. IFNAR1−/−: 0.8 ±
0.06-fold, p = 0.0002, n = 3 per genotype, Fig. 6c). Collect-
ively this data suggests that type-1 IFN signaling regulates
the pro-inflammatory glial response to Aβ1-42.
Wildtype glia adopt a pro-inflammatory phenotype in
response to Aβ1-42, whereas IFNAR1−/− cultures display
enhanced expression of anti-inflammatory phenotypic
markers
Within the current study we have demonstrated that
removal of IFNAR1 confers an anti-inflammatory glialresponse in APPSWE/PS1ΔE9 mice. Thus we were inter-
ested in confirming this phenotype in Aβ1-42-treated
IFNAR1−/− glial cultures that display attenuated pro-
inflammatory responses. To analyze the polarization
phenotype in response to Aβ1-42, wildtype and IFNAR1
−/− glial cultures were treated with 10 μM Aβ1-42 for
24–96 h and analyzed by Q-PCR.
Significantly, expression of the iNOS pro-inflammatory
marker was elevated in wildtype but not IFNAR1−/− glial
cultures in response to Aβ1-42 (24 h: Wildtype: 5.4 ± 2.8-
fold vs. IFNAR1−/−: 1.1 ± 0.3-fold, p = 0.0195; 48 h: Wild-
type: 5.9 ± 2.3-fold vs. IFNAR1−/−: 0.6 ± 0.06-fold, p =
0.0032, n = 4–5 per genotype, Fig. 7a). Transcript levels of
the CD11b pro-inflammatory marker were also elevated in
Aβ1-42-treated wildtype cultures but not when IFNAR1
was absent (72 h: Wildtype: 3.6 ± 0.9-fold vs. IFNAR1−/−:
0.7 ± 0.2-fold, p = 0.0274; 96 h: Wildtype: 4.1 ± 1.2-fold vs.
IFNAR1−/−: 0.8 ± 0.2-fold, p = 0.0083, n = 4–5 per genotype,
Fig. 7a). Expression levels of the CD32 pro-inflammatory
marker were also reduced in IFNAR1−/− glial cultures when
compared to wildtype counterparts upon Aβ1-42 insult
(96 h: Wildtype: 4.6 ± 1.4-fold vs. IFNAR1−/−: 1.4 ± 0.2-fold,
p = 0.0054, n = 4–5 per genotype, Fig. 7a).
Analysis of the ARG1 anti-inflammatory marker re-
vealed elevated expression levels in Aβ1-42-treated
IFNAR1−/− glia but not wildtype cultures (72 h: Wild-
type: 0.8 ± 0.5-fold vs. IFNAR1−/−: 2.9 ± 0.9-fold, p =
0.0252; 96 h: Wildtype: 1.3 ± 0.7-fold vs. IFNAR1−/−: 3.5
± 0.5-fold, p = 0.0163, n = 4–5 per genotype, Fig. 7b).
CCL22 anti-inflammatory marker expression levels were
also elevated in Aβ1-42-treated IFNAR1−/− glia but not
wildtype cultures (24 h: Wildtype: 1.0 ± 0.3-fold vs.
IFNAR1−/−: 2.5 ± 0.5-fold, p = 0.0089, n = 4–5 per geno-
type, Fig. 7b). Expression levels of the anti-inflammatory
markers YM1 and TGF-β remained constant across all
time points and between genotypes (n = 4–5 per genotype,
Fig. 7b). Expression levels of the CD206 anti-
inflammatory marker were elevated in response to Aβ1-42
treatment but no difference between culture genotype was
detected (n = 4–5 per genotype, Fig. 7b). Expression levels
of the TGFβ anti-inflammatory marker remained constant
across all time points and between genotypes (n = 4–5 per
genotype, Fig. 7b). Collectively these data suggest that
wildtype glia adopt a mixed inflammatory polarization
phenotype in response to amyloid insult. Removal of
IFNAR1 shifts this mixed population towards a predomin-
antly anti-inflammatory polarization state.
Conditioned media from Aβ1-42-treated IFNAR1−/− primary
glia is less toxic to primary cultured neurons than wildtype
media
To investigate the contribution of the glial polarized in-
flammatory response to Aβ1-42 on neuronal viability,
primary wildtype and IFNAR1−/− mixed glial cultures
Fig. 7 Aβ1-42 induces a pro-inflammatory phenotype in primary cultured glia with removal of IFNAR demonstrating a predmoninatly anti-inflammatory
response. a Q-PCR of primary wildtype and IFNAR1−/− glial cultures treated with 10 μM Aβ1-42 for 24–96 h analyzing iNOS, CD11b and
CD32 pro-inflammatory glial marker expression levels. b Q-PCR of primary wildtype and IFNAR1−/− glial cultures treated with 10 μM Aβ1-42 for 24–96
h analyzing ARG1, CCL22, YM1, CD206 and TGFβ anti-inflammatory glial marker expression levels. For Q-PCR all samples were normalized back to the
Ct value of the housekeeping gene GAPDH (ΔCt). The mRNA of the Aβ1-42 treatment groups was then expressed relative to their gene-specific vehicle
controls (fold change, ΔΔCt). Data are displayed as mean ± SEM (n = 4 (wildtype), n = 5 (IFNAR1−/−); *p < 0.05, **p < 0.01). See Additional file 2: Table S1
for further analysis
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was collected. Primary wildtype neuronal cultures were
then supplemented with this media for 48 h and an
MTS assay was performed to assess cellular viability.
Significantly, treatment of neurons with wildtype glial
conditioned media induced severe cytotoxicity that was
attenuated when the same neurons were supplemented
with IFNAR1−/− glial conditioned media (24 h media:
Wildtype: 28.9 ± 1.2 % vs. IFNAR1−/−: 77.8 ± 5.7 %, p =
0.0003; 48 h media: Wildtype: 18.4 ± 1.9 % vs. IFNAR1
−/−: 85.1 ± 7.1 %, p = 0.0001, n = 3 individual neuronal
and glial cultures per genotype, Fig. 8). Both genotypes
showed equal susceptibility to staurosporine-induced
apoptosis. This data implies that the reduced Aβ1-42-induced pro-inflammatory cytokine burden and anti-
inflammatory activity identified in IFNAR1−/− glia is pro-
tective to neurons in vitro.
Discussion
The precise mechanism of how Aβ drives neurotoxicity
and exacerbation of AD remains largely unknown.
Neuro-inflammation has been routinely implicated in
AD and is gaining credence as a major facilitator of dis-
ease progression [25, 41, 46, 47]. Type-1 IFNs are master
regulators of the innate immune response [33] regulating
IL-1β, IL-6 and TNFα cytokine secretion that remain
up-regulated in AD [42, 43]. The present study was de-
signed to test the hypothesis that type-1 IFN signalling
Fig. 8 Aβ1-42-conditioned media from IFNAR1−/− glia induces less neurotoxicity than wildtype counterparts. Primary wildtype and IFNAR1−/− glial
cultures were treated with 10 μM Aβ1-42 for 24–48 h and conditioned media was transferred to primary cultured wildtype neurons. An MTS assay
was performed to assess cellular viability of neuronal cultures. Apoptosis-inducing staurosporine treatment was utilized as a cytotoxic positive
control. Data are displayed as mean ± SEM (n = 3 per genotype (independent glial and neuronal primary cultures); ***p < 0.001). See Additional file
2: Table S1 for further analysis
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ology in the APPSWE/PS1ΔE9 mouse model of AD. To
address this hypothesis we generated APPSWE/PS1ΔE9 x
IFNAR1−/− mice lacking type-1 IFN signaling. We iden-
tified that these mice were protected from spatial learn-
ing and memory deficits demonstrated by APPSWE/
PS1ΔE9 mice. Interestingly, this phenotypic rescue did
not correlate with alterations in Aβ plaque burden and
only modest reductions in soluble cortical Aβ monomers
were detected. Additionally, removal IFNAR1 in the
APPSWE/PS1ΔE9 mouse promoted cortical astrocyte re-
activity, decreased total microgliosis, and conferred a
largely anti-inflammatory glial phenotype. These findings
were corroborated with IFNAR1−/− glial cultures initiat-
ing a predominantly anti-inflammatory response to
in vitro Aβ1-42 insult (Fig. 9).
Our observation that removal of IFNAR1 in APPSWE/
PS1ΔE9 mice alters many aspects of the neuro-
inflammatory response, improves performance in the
MWM behavioural test paradigm, but does not signifi-
cantly alter amyloid pathology is notable. Whilst it is
clear that amelioration of amyloidosis in the majority of
preclinical AD models results cognitive benefit, we
speculate that alleviating the pro-inflammatory burden
on the CNS alone is sufficient to rescue at least some of
the cognitive impairment demonstrated in these models.
We demonstrate that IFNα and IRF7 are up-regulated in
APPSWE/PS1ΔE9 mice and this expression is attenuated
upon removal of IFNAR1. Crucially, IRF7 is considered
a central mediator of the deleterious type-1 IFN re-
sponse on neurogenesis and cognition in old mice that
lack amyloid deposition; a phenotype rescued upon anti-
IFNAR1 monoclonal antibody treatment [3]. Thus
modulation of the type-1 IFN signalling system and sub-
sequent neuro-inflammatory responses may be sufficientin providing cognitive benefit irrespective of the clear-
ance of Aβ. However, we cannot rule out the modest, al-
beit significant, reduction in Aβ monomer levels
observed in the APPSWE/PS1ΔE9 x IFNAR1
−/− mice and
its potential effect on cognition. Indeed, targeted re-
moval of soluble Aβ production in aged tetracycline-
inducible APPSWE (Tg2576) mice reverts spatial learning
and memory impairments in the MWM without affect-
ing plaque burden [21]. Thus further studies involving
mass spectrometry profiles and electron microscopy of
Aβ species produced in APPSWE/PS1ΔE9 x IFNAR1
−/−
may provide insight on the mechanisms by which type-1
IFN signalling potentially influences Aβ oligomerization
and cognition.
The identification of attenuated plaque-localised
microgliosis, a predominant anti-inflammatory glial
phenotype combined with enhanced plaque-localised
astrocytic reactivity in APPSWE/PS1ΔE9 x IFNAR1
−/−
mice is also of interest. We confirm downregulated ex-
pression of pro-inflammatory (iNOS, CD11b and CD33)
and up-regulations of anti-inflammatory glial phenotypic
markers (TGFβ, YM1, ARG1 and TREM2) upon re-
moval of IFNAR1 in APPSWE/PS1ΔE9 mice. Many studies
suggest that this glial phenotypic shift results in en-
hanced Aβ phagocytosis and clearance, yet we do not
observe this. One possible explanation is that the anti-
inflammatory microglial activity may be counteracted by
enhanced astrocyte reactivity and elevated IL-1β secre-
tion, known to promote amyloidosis in APPSWE/PS1ΔE9
mice [26]. Indeed type-1 IFNs are pleiotropic in nature
and induce cell-type specific functions [49]. Whilst this
study focuses on the pro-inflammatory role of these cy-
tokines it is equally feasible that type-1 IFNs are also
exhibiting beneficial anti-inflammatory activity in spe-
cific cell types. There are currently 14 known IFNα
Fig. 9 Schematic of the modulated neuro-inflammatory environment in APPSWE/PS1ΔE9 x IFNAR1
−/− mice. The current study provides evidence
that a type-1 IFN response contributes to the neuro-inflammation observed in AD. Amyloid plaques and soluble Aβ1-42 within the plaque
microenvironment triggers pro-inflammatory microglial activation and secretion of pro-inflammatory cytokines, initiating the neuro-inflammatory
process. The pro-inflammatory cues within the plaque microenvironment further enhance gliosis, exacerbating inflammation. In AD, excessive Aβ
production maintains the stimulus for a pro-inflammatory response, compromising resolution, and contributes to a self-perpetuating
neuro-degenerative inflammatory cycle. The current study demonstrates that type-1 IFN signaling intricately controls this neuro-inflammation. Removal
of IFNAR1 in APPSWE/PS1ΔE9 mice reduced type-1 IFN production, TNFα expression and conferred an anti-inflammatory and neuro-protective
anti-inflammatory activation state of microglia. Enhanced astrocyte reactivity and IL-1β expression, but decreased total microgliosis, was also
demonstrated in these mice which were protected from spatial learning and memory deficits at 9 months of age
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IFNβ isoform, that in the majority of cases require
IFNAR1 for signalling. Thus the mixed inflammatory
phenotype we observe in our global IFNAR1 knockout
approach in APPSWE/PS1ΔE9 mice is likely due to signal-
ling elimination of these type-1 IFN subtypes and their
pleiotropic effects in multiple cell types. Further studies
identifying specific type-1 IFN subtypes and their contri-
bution to neuro-inflammatory cascades and potential
impact on amyloidosis will be beneficial in understand-
ing the progression of AD.
Stimulation of primary mixed glial cultures lacking
IFNAR1 with Aβ1-42 results in a predominantly anti-
inflammatory response as observed in vivo. We demon-
strate that the IFNAR1−/− glial response to Aβ1-42challenge is neuro-protective compared to the wildtype
pro-inflammatory response in our conditioned media
paradigm. We propose two alternative explanations for
the protection observed in this assay: 1) IFNAR1−/− glia
are more effective at removing Aβ1-42 from the media
than wildtype cultures, resulting in less Aβ1-42 transfer
to neuronal cultures and subsequent reduction in neuro-
toxicity. 2) Aβ1-42 insult triggers a reduced pro-
inflammatory response from IFNAR1−/− glia compared
to wildtype cultures, meaning that cytokine concentra-
tions are reduced when transferred onto neurons result-
ing in neuroprotection. Indeed, the phenotype observed
may be resultant from a combination of these two expla-
nations and warrants further experimentation to explore
this neuro-protective mechanism.
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strength of the current study, enabling conclusions
based on the effect of complete removal of type-1 IFN
signaling, this also remains a limitation as the central and
peripheral cellular contribution to neuro-inflammation in
APPSWE/PS1ΔE9 mice cannot be separated. Indeed, periph-
eral T-regulatory FoxP3+ve cells appear to breach the CSF-
blood brain barrier and their presence within the CNS
impacts AD pathology [4]. Considering the important role
of type-1 IFN signaling in T-cell activity [16], analyzing
these cell types and other peripherally invading immune
cells will be crucial in further deciphering the role of type-
1 IFN signaling in progression of AD. In addition, it will
be important to decipher the impact of reduced endogen-
ous murine APP levels in APPSWE/PS1ΔE9 x IFNAR1
−/−
mice, although endogenous Aβ production appears not to
influence pathology in mice carrying both mutant APP
and PS1 alleles [39].
Conclusion
The mechanisms by which neuro-neuroinflammation
contributes to AD exacerbation and progression is
highly complex and far from being fully understood. We
provide evidence that removal of type-1 IFN signalling
in the APPSWE/PS1ΔE9 mouse model of AD confers a
predominantly anti-inflammatory glial response and pro-
tects from cognitive decline. However our finding that
this phenotype does not correlate with alterations in
amyloid deposition and only a modest reduction in Aβ
monomer levels requires further investigation. Decipher-
ing the exact contribution of type-1 IFN isoforms and
cell types involved in the neuro-inflammatory response
will benefit our understanding of AD pathogenesis and
enhance our ability to target type-1 IFN signalling in
numerous neuro-inflammatory disorders.
Additional files
Additional file 1: Figure S1. Generation and confirmation of the
APPSWE/PS1ΔE9 x IFNAR1
−/− mouse. A) To generate a colony of C57BL/6
APPSWE/PS1ΔE9 x IFNAR1
−/− mice with appropriate IFNAR1−/− littermate
controls, heterozygous APPSWE/PS1ΔE9 mice were bred to mice homozygous
for the IFNAR1 gene disruption (neomycin insert; IFNAR1−/−). The subsequent
litters were termed F1 progeny and were expected to yield mice
heterozygous for both the APPSWE/PS1ΔE9 mutation and IFNAR1-neoE5 allele
(25 % male and 25 % female according to Mendelian inheritance). Upon
genetic confirmation, APPSWE/PS1ΔE9 (het) x IFNAR1
+/− mice were then
interbred to generate the first APPSWE/PS1ΔE9 x IFNAR1
−/− mice from F2 pro-
geny (6.25 % male and 6.25 % female according to Mendelian inheritance).
APPSWE/PS1ΔE9 (het) x IFNAR1
−/− mice were then interbred to generate F3
progeny consisting of APPSWE/PS1ΔE9 x IFNAR1
−/− (75 %) and IFNAR1−/−
(25 %) littermates. B) Genotyping results for the initial progeny containing
APPSWE/PS1ΔE9 x IFNAR1
−/− and littermate IFNAR1−/− mice is displayed.
Genotyping PCR was performed using a combined APPSWE/PS1ΔE9 and
IFNAR1−/−. For each mouse, genotyping for APPSWE, PS1ΔE9 and IFNAR1
expression was performed in separate reactions with internal control (IC)
amplification (APPSWE reactions only). The expected band sizes were as
follows: APPSWE: 377 bp, PS1ΔE9: 608 bp, wildtype IFNAR1: 351 bp, IFNAR1-neomycin (IFNAR1−/−): 985 bp and IC: 324 bp. APP positive bands in lanes 2,
8 and 12 are comprised of both APPSWE and IC bands as indicated in the
fig. C) Immunoblotting of Tris–HCl soluble cortical brain extracts, using mAb
WO-2, revealed effective APP overexpression in APPSWE/PS1ΔE9 x
IFNAR1−/− mice that was indistinguishable from levels in APPSWE/
PS1ΔE9 mice. (TIF 6948 kb)
Additional file 2: Table S1. Statistical table (See additional statistical
table file). Statistical analysis information is displayed for all data displayed
within the accompanying figures. Power values were determined post-hoc
based upon population effect size, sample size and group number. An α
value of 0.05 was used to set the type-1 error rate in statistical comparisons.
p values are given as exact values or adjusted multiplicity variants where an
ANOVA and multiple comparisons post-hoc test was applied to the data. n
represents the number of individual animals or primary cell cultures
derived from separate animals used in each experiment. N/A: not
applicable. (XLSX 49 kb)
Additional file 3: Figure S2. IFNβ mRNA transcript levels are unaltered
in cortical tissue 9 month old APPSWE/PS1ΔE9 mice. Q-PCR of cortical
tissue isolated from 9 month old wildtype and APPSWE/PS1ΔE9 mice ana-
lyzing IFNβ mRNA levels. For Q-PCR, all samples were normalized back to
the Ct value of the housekeeping gene GAPDH (ΔCt). The mRNA of the
variant genotype groups were then expressed relative to their gene-specific
wildtype littermate controls (fold change, ΔΔCt). Data are displayed as box
plots box plots described in the statistical analysis section in Materials and
Methods (n = 7 per genotype) See Additional file 2: Table S1 for further
analysis. (TIF 213 kb)
Additional file 4: Figure S3. Aβ1-42 does not induce a p-Stat-3 mediated
response in either wildtype or IFNAR1−/− primary glial cultures. A) Representa-
tive immunoblot of primary wildtype and IFNAR1−/− glial cultures treated
with 10 μM Aβ1-42 for 24–72 h using anti-p-Stat-3. B) Densitometry of p-Stat-
3 levels in primary wildtype and IFNAR1−/− glial cultures treated with 10 μM
Aβ1-42 for 24–72 h. For densitometry, total Stat-3 levels were normalized to
the β-actin loading control and p-Stat-3 intensity was calculated relative to
this value (p-Stat-3/(Stat-3/β-actin). All intensity values of Aβ1-42 treated
groups are expressed as fold change relative to the genotype-specific vehicle
control (average of which is represented by the dashed line). Immunodetec-
tion of β-actin was used to ascertain loading quantities. Data are displayed as
mean ± SEM (n= 3 per genotype). See Additional file 2: Table S1 for further
analysis. (TIF 4277 kb)Abbreviations
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